Skip to main content

Table 5 OS (overall survival) according to  KRAS  mutation for the two different treatment arms

From: Effect of KRAS codon13 mutations in patients with advanced colorectal cancer (advanced CRC) under oxaliplatin containing chemotherapy. Results from a translational study of the AIO colorectal study group

OS

FUFOX

CAPOX

p-value (log rank)

 

n = 105

n = 96

HR (95% CI)

WT

24.2months

18.9months

0.31

   

0.79 (0.51-1.24)

Codon 12

15.6months

15.5months

0.54

mutation

  

0.83 (0.45-1.53)

Codon 13

16.1months

16.5months

0.62

mutation

  

1.39 (0.37-5.37)

  1. OS, HR hazard ratio by cox regression, CI confidence interval.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us